NASDAQ OMX

Nxchange launches new stock exchange

Dela

Nxchange is introduces a next generation stock exchange for direct trading in securities between companies and investors. Nxchange operates under a licence issued by
 the Dutch Ministry of Finance as a regulated market.

Amsterdam, 27 April 2016 - As of now, European companies listed on Nxchange can use their own websites to raise capital in their own networks and communities. Fastned, the national fast charger network in the Netherlands, was the first company to be admitted for listing.

The arrival of Nxchange makes it possible to place and trade securities on a regulated platform without the intervention of a bank or broker being required. Companies can activate their network and communities to raise capital both on the central trading platform of Nxchange and using an integrated module on their own websites. A traditional IPO is usually an expensive and complex matter. Nxchange has identified a need for an alternative that brings companies and investors closer together. "In the era of social networking it makes sense to come up with a solution for securities trading in which companies and investors can maintain direct contact with each other", says Marleen Evertsz, CEO of Nxchange.

Nxchange combines the positive aspects of crowdfunding with the benefits of a regulated stock exchange. As well as a primary market, it offers a secondary market in a transparent, liquid and regulated setting. Investment is all about confidence in good entrepreneurship. Evertsz continues: "Companies wanting to be listed on Nxchange opt for unprecedented transparency that makes it possible for investors to make well-founded investment decisions." Investors can ask questions directly to the company via a public Q&A and the company in turn can enter into a direct dialogue with its investors. All financial information and underlying documents are available on the platform, through which the company can directly distribute important information to stakeholders. The (social media) sentiment surrounding the issuing organisation is clarified and analysts' reports are available on the fund page. The platform also provides a forum on which investors can communicate with each other and exchange ideas. Nxchange thus provides a level playing field for all parties.

Nxchange makes companies less dependent on traditional financial service providers and gives them more efficient access to capital that centres less on speculation than a traditional stock exchange. Nxchange offers investors transparency and investment options that were previously only available to a limited group of investors. The trading platform also facilitates the mutual trading of securities in a secondary market.

Evertsz concludes: "Our country's innovative business climate calls for an innovative stock market. We therefore expect to approach ten listings as early as in 2016 and will occupy a pan-European positioning from the very beginning."

Nxchange is launched as the stock exchange of the future with the first listing of Fastned. The platform is open to companies of any size that meet the listing requirements. It will be open for trading 24 hours a day, 7 days a week, and transactions will be settled in realtime. Nxchange works in partnership with Euroclear as the custodian bank. Nxchange has been approved by the Dutch Ministry of Finance as a regulated market.

Media relations Nxchange,:
Carolien Pors, carolien@porscommunicatie.nl, +31 (0)6 106 503 34

For more information about Nxchange:
https://www.nxchange.com, +31 (0)20 240 4362

For more information about Fastned:
https://fastned.nl/en/nxchange, +31 (0)20 705 5320




This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nxchange via Globenewswire

HUG#2006843

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

Barings Supports New Mountain Capital Investment in DRB Systems17.10.2017 16:30Pressmeddelande

CHARLOTTE, N.C., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Barings, one of the world's leading asset management firms, announced today that it served as a Joint Lead Arranger on a Senior Secured Credit Facility to support New Mountain Capital's acquisition of DRB Systems LLC.                                                               Founded in 1984 and based in Akron, Ohio, DRB Systems is the leading provider of turnkey technology solutions used to enhance the operational efficiency of car wash sites across the U.S.  DRB's integrated technology offering includes hardware and software used in point-of-sale and tunnel control systems as well as ancillary modules to support marketing, human resources, and business analytics. "New Mountain Capital is pleased to have completed its investment in DRB Systems," said Jack Qian, Director of New Mountain Capital. Laura Holson, Head of Capital Markets at New Mountain added, "We deeply value Barings' support as a financing pa

Crown Bioscience to Showcase Scientific Expertise in Preclinical Evaluation of Investigational Cancer Compounds17.10.2017 16:12Pressmeddelande

SANTA CLARA, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will showcase their scientific expertise at this year's American Association for Cancer Research's International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC) October 26th through the 30th. CrownBio's scientists will present 13 scientific posters describing their latest research efforts, including generation of novel models for combinatory chemotherapy and immunotherapy studies, creation of 3D screening panels for improved efficacy assessments, demonstration of a checkpoint immunotherapy modulating intestinal microbiota, among other innovative developments in cancer therapeutics and preclinical pharmacology evaluation. On

Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 201717.10.2017 15:15Pressmeddelande

OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that it plans to release third quarter 2017 financial results prior to market open on Tuesday, October 31, 2017.  Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 99539511, approximately ten minutes prior to start time.  To access the live audio webcast or subsequent archived recording, visit the Investor Relations se

World Conference on Lung Cancer Tuesday Press Conference: Evidence to Support Innovative Lung Cancer Interventions17.10.2017 08:16Pressmeddelande

YOKOHAMA, Japan, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Today's press conference at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) featured groundbreaking findings in the study of both small cell and non-small cell lung cancer. The studies presented covered broad research areas, from confirmation of existing classification criteria to ensuring viability of evidence to supporting the use of specific interventions. Biopsy specimen found to be reliable for evaluating DLL3 expression in small cell lung cancer Small cell lung cancer (SCLC) biopsy specimen was found to be reliable material for evaluating DLL3 expression; high levels of DLL3 in SCLC are correlated with poor survival trends. These results may lead to further evaluation of the scoring system for predicting DLL3-targeted therapeutic efficacy and clinical significance of DLL3 expression in high-grade pulmonary neuroendocrine carcinomas.

New Era Launches Direct-to-Consumer eCommerce Site Built by EPAM and Powered with SAP Hybris17.10.2017 06:01Pressmeddelande

New Site Expands Headwear and Apparel Offering with Immersive, Omnichannel Experience NEWTOWN, Pa., Oct.  17, 2017  (GLOBE NEWSWIRE) -- EPAM Systems, Inc. (NYSE:EPAM), a leading global provider of digital platform engineering and software development services, and New Era, a global headwear brand rooted in sports, today announced the launch of New Era's first direct-to-consumer website, neweracap.com. New Era's B2B business remains strong, and the company is now putting an emphasis on selling its products directly to customers and expanding its offering into the lifestyle market. The new site offers products for seasoned athletes and sports fans, as well as street and lifestyle consumers. "In an age where businesses cannot tolerate lengthy, scope changing technology projects, EPAM quickly established themselves as the standout partner for us to tackle this ambitious initiative," said Lorenz Gan, Global Vice President, Information Technology, New Era. "Whilst this p

CP Kelco Appoints Didier Viala as New President16.10.2017 15:00Pressmeddelande

ATLANTA, Oct. 16, 2017 (GLOBE NEWSWIRE) -- CP Kelco, a leading global producer of specialty hydrocolloid solutions, announced today that Didier Viala has been appointed President, effective October 1, 2017. Viala replaces Donald Rubright, who served as CP Kelco President since 2006 and will retire at the end of 2017. Viala has also joined the CP Kelco Board of Directors. "As a market leader supplying high-quality hydrocolloid products for a range of foods and beverages, consumer products and industrial applications, CP Kelco will continue to invest in capacity additions, new product and applications development, strategic raw material sourcing, quality and safety management, and sustainability initiatives to support our customers' innovation efforts and growth strategies," Viala said. Over the course of more than 25 years with CP Kelco and its predecessor companies, Viala held leadership roles across a broad spectrum of critical areas, including innovat

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum